CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 15/3087% below fair value
$4.66−0.18 (-3.72%)
Close on Nov 13, 2026Market cap $363.22MP/E –Yield –
CorMedix profit margin
Profit margin (net margin) is net income as a percentage of revenue.
CorMedix's profit margin for the twelve months ending Sep 30, 2026 was 15.5%. For fiscal 2025 it was 52.3%, against -41.2% the year before. The highest annual figure on record is 52.3% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.3% | +93.6 |
| FY2024 | Dec 31, 2024 | -41.2% | +45368.7 |
| FY2022 | Dec 31, 2022 | -45409.9% | −30635.2 |
| FY2021 | Dec 31, 2021 | -14774.7% | −5567.0 |
| FY2020 | Dec 31, 2020 | -9207.7% | −3406.4 |
| FY2019 | Dec 31, 2019 | -5801.3% | +441.1 |
| FY2018 | Dec 31, 2018 | -6242.4% | +3781.1 |
| FY2017 | Dec 31, 2017 | -10023.4% | +973.0 |
| FY2016 | Dec 31, 2016 | -10996.5% | −2341.1 |
| FY2015 | Dec 31, 2015 | -8655.4% | +2150.9 |
| FY2014 | Dec 31, 2014 | -10806.3% | +445620.4 |
| FY2013 | Dec 31, 2013 | -456426.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -27.0% | −131.1 |
| Q2 FY2026 | Jun 30, 2026 | 25.5% | −24.4 |
| Q1 FY2026 | Mar 31, 2026 | 30.3% | −22.5 |
| Q4 FY2025 | Dec 31, 2025 | 10.9% | −32.2 |
| Q3 FY2025 | Sep 30, 2025 | 104.1% | +128.3 |
| Q2 FY2025 | Jun 30, 2025 | 49.9% | +1805.4 |
| Q1 FY2025 | Mar 31, 2025 | 52.8% | +27690.5 |
| Q4 FY2024 | Dec 31, 2024 | 43.1% | +100581.8 |
| Q3 FY2024 | Sep 30, 2024 | -24.2% | +35758.2 |
| Q2 FY2024 | Jun 30, 2024 | -1755.5% | +90363.3 |
| Q4 FY2022 | Dec 31, 2022 | -27637.7% | −13823.2 |
| Q3 FY2022 | Sep 30, 2022 | -100538.7% | −78039.8 |
| Q2 FY2022 | Jun 30, 2022 | -35782.4% | +20778.9 |
| Q1 FY2022 | Mar 31, 2022 | -92118.8% | −83942.0 |
| Q4 FY2021 | Dec 31, 2021 | -13814.5% | −2889.2 |
| Q3 FY2021 | Sep 30, 2021 | -22498.9% | −15402.8 |
| Q2 FY2021 | Jun 30, 2021 | -56561.3% | −33558.0 |
| Q1 FY2021 | Mar 31, 2021 | -8176.8% | −672.1 |
| Q4 FY2020 | Dec 31, 2020 | -10925.3% | +10481.5 |
| Q3 FY2020 | Sep 30, 2020 | -7096.1% | +1748.0 |
| Q2 FY2020 | Jun 30, 2020 | -23003.2% | −21029.2 |
| Q1 FY2020 | Mar 31, 2020 | -7504.7% | −4347.7 |
| Q4 FY2019 | Dec 31, 2019 | -21406.8% | −29507.4 |
| Q3 FY2019 | Sep 30, 2019 | -8844.0% | −6096.2 |
| Q2 FY2019 | Jun 30, 2019 | -1974.0% | +111347.5 |
| Q1 FY2019 | Mar 31, 2019 | -3157.1% | +40725.4 |
| Q4 FY2018 | Dec 31, 2018 | 8100.6% | +19244.0 |
| Q3 FY2018 | Sep 30, 2018 | -2747.8% | +13554.0 |
| Q2 FY2018 | Jun 30, 2018 | -113321.6% | −109542.3 |
| Q1 FY2018 | Mar 31, 2018 | -43882.5% | −24678.6 |
| Q4 FY2017 | Dec 31, 2017 | -11143.4% | −5854.9 |
| Q3 FY2017 | Sep 30, 2017 | -16301.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -3779.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -19203.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -5288.4% | – |
See a number that looks wrong?